Silo Pharma Inc.

04/29/2026

Silo Pharma (Nasdaq: SILO) commends a wave of coordinated U.S. federal actions that are rapidly advancing the development of psychedelic-based therapeutics for mental health and substance use disorders. Building on last weekend’s executive initiative to fast-track these treatments, multiple agencies have taken meaningful steps this week to accelerate research, clinical progress, and regulatory clarity across the sector.

These actions point to a broader shift across funding, clinical advancement, and regulatory prioritization in the development of new treatments for PTSD and related disorders.

Read more: https://ir.silopharma.com/single-news-releases/?webmasterId=104586&qmodStoryID=5172080466485565

05/28/2025

Silo Pharma & Resyca Partner for a drug-device study of the formulation-specific microchip-based nasal spray system used in its lead asset SPC-15, an intranasal prophylactic treatment for PTSD.

Read more:

Silo Pharma (Nasdaq: SILO) partnered with Resyca BV to conduct a drug-device study for their lead asset, SPC-15, an...

05/22/2025

Did you know there has not been a new drug approval for PTSD in nearly 25 years, affecting an estimated 3.9% of the world’s population? Silo is addressing this unmet need with SPC-15, a prophylactic treatment for PTSD.

Learn about SPC-15’s potential: https://bit.ly/3RMCdVh

05/21/2025

Silo Pharma (Nasdaq: SILO) Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15. Read the press release here: https://bit.ly/3FnTII8

05/20/2025

Silo’s clear timeline to first-in-human clinical trials for lead asset SPC-15, an intranasal prophylactic treatment for PTSD, is pending FDA guidance on pre-IND.

Stay updated on the latest SPC-15 development news: https://bit.ly/48iQ5M9

05/15/2025

Silo Pharma reaches clear regulatory path to clinical trials for intranasal PTSD therapy, SPC-15

We've initiated the FDA-requested 7-day safety and toxicology study at Frontage Laboratories, supplementing our ongoing GLP-compliant toxicokinetic studies of SPC-15.

Positive preclinical data from these studies, if achieved, would support an IND submission for SPC-15 in 2025. Should Silo receive approval of the IND, Silo would proceed to a first-in-human Phase 1 clinical trial for SPC-15.

Read our full announcement: https://bit.ly/457iMxx

05/15/2025

Silo has a disruptive market potential in the central nervous system therapeutics industry with a projected CAGR of 10.5% for CNS drugs during the period 2025 (~$155.5 B) to 2034 (~$381.3 B).

Learn more: https://bit.ly/3YCAEws

05/14/2025

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15. Read the press release here: https://bit.ly/3YK4Ndh

05/14/2025

Silo Pharma (Nasdaq: SILO) Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories.

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market.

Read the press release here: https://bit.ly/457iMxx

05/12/2025

Silo’s four novel drug candidates address underserved medical needs including mental health, neurology and chronic pain.

Discover how Silo’s pipeline of therapeutics are targeting PTSD, stress-induced psychiatric disorders and Alzheimer’s Disease: https://bit.ly/3DMYOKp

05/05/2025

Silo CEO Eric Weisblum comments on preclinical study evaluating SP-26: “We believe these results support the advancement of SP-26 as a next-generation therapeutic for fibromyalgia, combining the proven efficacy of ketamine with the safety and convenience of extended-release delivery.

SP-26 has been designed to offer a new approach to pain management by providing sustained, sub-psychedelic levels of ketamine in an abuse-deterrent format. Preclinical SP-26 research overall has focused on ensuring that the safety profile of SP-26 aligns with FDA requirements for potential at-home therapeutic designation. If approved, SP-26 could become the first at-home injectable ketamine-based therapeutic.”

Read more: https://bit.ly/3GsMDpV

05/02/2025

Silo announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.

All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation.

In case you missed it, read the press release here: https://bit.ly/3GsMDpV